B244

BIOLOGICAL7 trials

Sponsors

AOBiome LLC

Conditions

Acne VulgarisAtopic DermatitisAtopic Dermatitis EczemaHypertension, Stage IMigrainePrehypertensionPruritusRosacea

Phase 1

A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris

CompletedNCT02656485

AOBiome LLCAcne Vulgaris

Start: 2015-08-05End: 2016-07-15Updated: 2017-04-05

Phase 2

Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris

CompletedNCT02832063

AOBiome LLCAcne Vulgaris

Start: 2016-08-31End: 2017-07-19Updated: 2022-09-16

A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure

CompletedNCT02998840

AOBiome LLCHypertension, Stage I, Prehypertension

Start: 2016-11-30End: 2017-06-26Updated: 2022-09-15

Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis

CompletedNCT03235024

AOBiome LLCAtopic Dermatitis Eczema

Start: 2018-01-15End: 2019-03-20Updated: 2022-10-10

Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine

CompletedNCT03488563

AOBiome LLCMigraine

Start: 2018-03-30End: 2019-07-16Updated: 2022-10-04

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

CompletedNCT03590366

AOBiome LLCRosacea

Start: 2018-07-02End: 2019-03-05Updated: 2022-09-16

B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

CompletedNCT04490109

AOBiome LLCAtopic Dermatitis, Pruritus

Start: 2020-06-24End: 2022-01-07Updated: 2025-01-28

Related Papers

Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial.

2023-05-1625 citations